309 related articles for article (PubMed ID: 27689018)
1. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration.
Villani LA; Smith BK; Marcinko K; Ford RJ; Broadfield LA; Green AE; Houde VP; Muti P; Tsakiridis T; Steinberg GR
Mol Metab; 2016 Oct; 5(10):1048-1056. PubMed ID: 27689018
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
3. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
O'Brien AJ; Villani LA; Broadfield LA; Houde VP; Galic S; Blandino G; Kemp BE; Tsakiridis T; Muti P; Steinberg GR
Biochem J; 2015 Jul; 469(2):177-87. PubMed ID: 25940306
[TBL] [Abstract][Full Text] [Related]
4. The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.
Hawley SA; Ford RJ; Smith BK; Gowans GJ; Mancini SJ; Pitt RD; Day EA; Salt IP; Steinberg GR; Hardie DG
Diabetes; 2016 Sep; 65(9):2784-94. PubMed ID: 27381369
[TBL] [Abstract][Full Text] [Related]
5. The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice.
Day EA; Ford RJ; Lu JH; Lu R; Lundenberg L; Desjardins EM; Green AE; Lally JSV; Schertzer JD; Steinberg GR
Biochem J; 2020 Jun; 477(12):2347-2361. PubMed ID: 32510137
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Mancini SJ; Boyd D; Katwan OJ; Strembitska A; Almabrouk TA; Kennedy S; Palmer TM; Salt IP
Sci Rep; 2018 Mar; 8(1):5276. PubMed ID: 29588466
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules.
Mori K; Saito R; Nakamaru Y; Shimizu M; Yamazaki H
Biopharm Drug Dispos; 2016 Nov; 37(8):491-506. PubMed ID: 27604638
[TBL] [Abstract][Full Text] [Related]
9. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Zügner E; Yang HC; Kotzbeck P; Boulgaropoulos B; Sourij H; Hagvall S; Elmore CS; Esterline R; Moosmang S; Oscarsson J; Pieber TR; Peng XR; Magnes C
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887308
[TBL] [Abstract][Full Text] [Related]
10. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin.
Papadopoli D; Uchenunu O; Palia R; Chekkal N; Hulea L; Topisirovic I; Pollak M; St-Pierre J
Neoplasia; 2021 Apr; 23(4):391-399. PubMed ID: 33784591
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin promotes osteoblastic MC3T3-E1 differentiation
Song P; Chen T; Rui S; Duan X; Deng B; Armstrong DG; Ma Y; Deng W
Front Endocrinol (Lausanne); 2022; 13():1081039. PubMed ID: 36589840
[TBL] [Abstract][Full Text] [Related]
12. AMPK β1 reduces tumor progression and improves survival in p53 null mice.
Houde VP; Donzelli S; Sacconi A; Galic S; Hammill JA; Bramson JL; Foster RA; Tsakiridis T; Kemp BE; Grasso G; Blandino G; Muti P; Steinberg GR
Mol Oncol; 2017 Sep; 11(9):1143-1155. PubMed ID: 28544264
[TBL] [Abstract][Full Text] [Related]
13. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.
Ali A; Mekhaeil B; Biziotis OD; Tsakiridis EE; Ahmadi E; Wu J; Wang S; Singh K; Menjolian G; Farrell T; Mesci A; Liu S; Berg T; Bramson JL; Steinberg GR; Tsakiridis T
Commun Biol; 2023 Sep; 6(1):919. PubMed ID: 37684337
[TBL] [Abstract][Full Text] [Related]
14. In vitro antiglioma action of indomethacin is mediated via AMP-activated protein kinase/mTOR complex 1 signalling pathway.
Pantovic A; Bosnjak M; Arsikin K; Kosic M; Mandic M; Ristic B; Tosic J; Grujicic D; Isakovic A; Micic N; Trajkovic V; Harhaji-Trajkovic L
Int J Biochem Cell Biol; 2017 Feb; 83():84-96. PubMed ID: 27988363
[TBL] [Abstract][Full Text] [Related]
15. Availability of the key metabolic substrates dictates the respiratory response of cancer cells to the mitochondrial uncoupling.
Zhdanov AV; Waters AH; Golubeva AV; Dmitriev RI; Papkovsky DB
Biochim Biophys Acta; 2014 Jan; 1837(1):51-62. PubMed ID: 23891695
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose.
Jiang W; Zhu Z; Thompson HJ
Mol Carcinog; 2008 Aug; 47(8):616-28. PubMed ID: 18247380
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways.
Wang Y; Yang L; Mao L; Zhang L; Zhu Y; Xu Y; Cheng Y; Sun R; Zhang Y; Ke J; Zhao D
Cancer Cell Int; 2022 Feb; 22(1):74. PubMed ID: 35148777
[TBL] [Abstract][Full Text] [Related]
18. SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake.
Albalawy WN; Youm EB; Shipman KE; Trull KJ; Baty CJ; Long KR; Rbaibi Y; Wang XP; Fagunloye OG; White KA; Jurczak MJ; Kashlan OB; Weisz OA
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1041-F1053. PubMed ID: 38660713
[TBL] [Abstract][Full Text] [Related]
19. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
[TBL] [Abstract][Full Text] [Related]
20. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]